NCT02952989 A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Status TERMINATED Phase PHASE1
NCT02950220 Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Status COMPLETED Phase PHASE1
NCT02949843 Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations Status TERMINATED Phase PHASE2
NCT02949219 Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02939651 A Study of Pembrolizumab in Patients With Neuroendocrine Tumors Status COMPLETED Phase PHASE2
NCT02936752 Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents Status COMPLETED Phase PHASE1
NCT02934503 Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) Status TERMINATED Phase PHASE2
NCT02933944 Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Status TERMINATED Phase PHASE1
NCT02930902 Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery Status COMPLETED Phase PHASE1
NCT02925533 Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Status TERMINATED Phase PHASE1
NCT02922764 A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer Status COMPLETED Phase PHASE1
NCT02921256 Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer Status COMPLETED Phase PHASE2
NCT02909452 Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02909348 Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab Status COMPLETED Phase N/A
NCT02907099 Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer Status COMPLETED Phase PHASE2
NCT02906332 Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) Status TERMINATED Phase PHASE2